James A Thomson

This inventor holds 80 USPTO granted patents and 27 published patent applications, plus 16 CIPO patents and 23 EPO patents, primarily in Pluripotent Stem Cells (CPC class C12N). Top assignees: Wisconsin Alumni Research Foundation, Wicell Research Institute, Inc., Polaris Group. Active years: 1976-2026.

USPTO Granted Patents = 80 (Patent Applications = 27)

% Patents Active = 92.5

CIPO Patents = 16 (Patent Applications = 4)

EPO Patents = 23 (Patent Applications = 27)

Average Co-Inventor Count = 2.3

ph-index = 19

Forward Citations = 2,285(Granted Patents)

Forward Citations (Not Self Cited) = 2,164(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Berkeley, CA (US) (1976)
San Diego, CA (US) (2009 - 2022)
Madison, WI (US) (1998 - 2024)

Company Filing History:

60 out of 4,226

Wisconsin Alumni Research Foundation

patents

5 out of 5

Wicell Research Institute, Inc.

Cellular Dynamics International, Inc.

8. 4 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 1976-2026

Loading Chart...

Areas of Expertise:

Hematopoietic Progenitor Cells

Microglia Derivation

Endothelial Cells

Hepatocyte Generation

Somatic Cell Reprogramming

Cancer Treatment

iPS Cells Production

Cell Culture Substrate

Neural Toxicity Models

Pegylated Arginine Deiminase

Genetic Variation

Dendritic Cells

80 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12734197 - Generation of uniform hepatocytes from human embryonic stem cells by inhibiting TGF-beta and methods of maintaining hepatic cultures (2026-09-15),

2. 12649906 - Human Pluripotent Stem Cell-Based Models for Predictive Developmental Neural Toxicity (2026-06-09),

3. 12497593 - Generation of hematopoietic progenitor cells from human pluripotent stem cells (2025-12-16),

4. 12454676 - Derivation of human microglia from pluripotent stem cells (2025-10-28),

5. 12410404 - Human pluripotent stem cell-based screening for smooth muscle cell differentiation and disease (2025-09-09),

6. 12370242 - Formulations of pegylated arginine deiminase (2025-07-29),

7. 12344645 - Protein conjugates (2025-07-01),

8. 11898162 - Reprogramming somatic cells into pluripotent cells using a vector encoding Oct4 and Sox2 (2024-02-13),

9. 11674123 - Generating arterial endothelial cell populations (2023-06-13),

10. 11566229 - Expansion and maintenance of adult primary human hepatocytes in culture (2023-01-31),

11. 11395866 - Generating arterial endothelial cell-seeded vascular grafts (2022-07-26),

12. 11235037 - Arginine deiminase with reduced cross-reactivity toward ADI - PEG 20 antibodies for cancer treatment (2022-02-01),

13. 11220672 - Human pluripotent stem cell-based system for generating endothelial cells (2022-01-11),

14. 11124765 - Derivation of human microglia from pluripotent stem cells (2021-09-21),

15. 11116799 - Generation of uniform hepatocytes from human embryonic stem cells by inhibiting TGF-beta and methods of maintaining hepatic cultures (2021-09-14),

Title: James A Thomson - Pioneering Innovator in Stem Cell Research

Introduction:

James A Thomson is a visionary inventor in the field of stem cell research, hailing from Madison, WI (US). With an impressive portfolio of 67 patents to his name, Thomson has made significant contributions to the scientific community.

Latest Patents:

1. Reprogramming somatic cells into pluripotent cells using a vector encoding Oct4 and Sox2: Thomson's innovative method focuses on reprogramming somatic cells to pluripotency by administering potency-determining factors. This breakthrough opens up new possibilities in regenerative medicine.

2. Generating arterial endothelial cell populations: Thomson's method for generating human arterial endothelial cells under specific conditions showcases his dedication to advancing research in the field. This invention holds promise for treating peripheral arterial disease and screening potential therapeutic agents.

Career Highlights:

Thomson's groundbreaking work has been showcased through his tenure at renowned establishments such as the Wisconsin Alumni Research Foundation and WiCell Research Institute, Inc. His relentless pursuit of excellence has established him as a trailblazer in the realm of stem cell technology.

Collaborations:

Throughout his illustrious career, Thomson has collaborated with esteemed professionals, including Igor I Slukvin and Maksym A Vodyanyk. These partnerships have led to innovative discoveries and further advancements in the field of stem cell research.

Conclusion:

James A Thomson's dedication to pushing the boundaries of scientific exploration and his commitment to revolutionizing stem cell research make him a pioneering figure in the realm of innovation. His patents and collaborations stand as a testament to his unwavering contribution to the field, shaping the future of regenerative medicine and beyond.